Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New torsemide formulation aims to ease bladder symptoms in heart failure

NCT ID NCT06206512

Symptom relief Sponsor: Sarfez Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an extended-release version of the diuretic torsemide works better than the standard immediate-release form for reducing overactive bladder symptoms in people with chronic heart failure. Twenty-four participants took each version for four weeks, tracking their urinary symptoms and quality of life. The goal was to see if the extended-release form causes fewer bladder problems while still managing fluid buildup.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
torsemide (extended release and immediate release)
What this could lead to
If it works, this could point toward a better-tolerated diuretic that reduces bothersome bladder symptoms in heart failure patients.
What could go wrong
This is a small, early Phase 2 trial with only 24 participants, so results may not apply widely. Torsemide can cause kidney injury, electrolyte loss, and hearing issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

24 people

The number who actually took part.

Started

Jun 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of either gender of ≥50 years with clinical diagnosis of CHF. * Patients with NYHA (New York Heart Association) functional class of II-IV. * Patients receiving stable dose of furosemide 40mg or 80mg. * Patients with an estimated glomerular filtration rate (eGFR) of ≥30 ml/min/1.73 m2. * Patients with symptoms of overactive bladder. Exclusion Criteria: * The patients with an estimated glomerular filtration rate (eGFR) below 30 ml/min/1.73 m2 * Any known allergy to diuretics or sulphonamide-derived compounds * Serum potassium concentration (K+) equal to or below 3.5 mEq/ L (mmol/L). * History of myocardial infarction or stroke within the preceding 3 months duration * Inability to comprehend or comply with the informed consent (including a physician's assessment of prior drug non-compliance). * Urinalysis containing white blood cells indicative of urinary tract infection * Patients with liver cirrhosis * Any bladder catheterization, bladder, or prostrate surgery and/or, bladder, prostate, or pelvic radiotherapy within the last 3 months duration * Patients who have participated in another clinical study in the past 3 months prior to commencement of this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic congestive heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure overactive bladder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Incontinence Overactive bladder

Contacts and locations

Locations

  • Cardiometabolic Research Unit

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.